Health Care • Biotechnology: Pharmaceutical Preparations
$25.17 ▼ -1.21
(-4.59%)
MKT CAP: $104.3M • VOL: 14.2K
52W L $20 52W H $44
VTVT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $1.0M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$32.8M | -$24.2M | -$25.5M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$27.0M | -$18.5M | -$20.3M |
| EBITDA (Normalized) | — | -$24.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.3M | -$25.3M | -$19.1M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$25.3M | -$25.3M | -$19.1M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $88.9M | $36.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $64.4M | $12.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VTVT.